Prothena Corp PLC
Company Profile
Business description
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer’s disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
Contact
77 Sir John Rogerson’s Quay
Block C
Grand Canal Docklands
Dublin 2D02 VK60
IRLT: +353 12362500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
163
Stocks News & Analysis
stocks
Our top ASX picks in every sector
stocks
Potentially catastrophic ruling for ASX company
stocks
4 charts on Nvidia’s record $4 trillion market cap
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,852.20 | 36.90 | 0.42% |
CAC 40 | 7,808.17 | 21.12 | -0.27% |
DAX 40 | 24,160.64 | 94.67 | -0.39% |
Dow JONES (US) | 44,459.65 | 88.14 | 0.20% |
FTSE 100 | 8,998.06 | 56.94 | 0.64% |
HKSE | 24,250.90 | 47.58 | 0.20% |
NASDAQ | 20,640.33 | 54.80 | 0.27% |
Nikkei 225 | 39,513.46 | 53.84 | 0.14% |
NZX 50 Index | 12,691.00 | 12.31 | 0.10% |
S&P 500 | 6,268.56 | 8.81 | 0.14% |
S&P/ASX 200 | 8,609.20 | 38.80 | 0.45% |
SSE Composite Index | 3,486.88 | 32.77 | -0.93% |